Brooktree Capital Management Sells 418 Shares of Eli Lilly and Company (NYSE:LLY)

Brooktree Capital Management decreased its position in Eli Lilly and Company (NYSE:LLY) by 9.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,206 shares of the company’s stock after selling 418 shares during the quarter. Eli Lilly and Company makes up 3.0% of Brooktree Capital Management’s portfolio, making the stock its 11th biggest holding. Brooktree Capital Management’s holdings in Eli Lilly and Company were worth $3,726,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Curi RMB Capital LLC grew its position in shares of Eli Lilly and Company by 9.9% during the 3rd quarter. Curi RMB Capital LLC now owns 6,981 shares of the company’s stock valued at $6,184,000 after acquiring an additional 628 shares during the period. Wealthstream Advisors Inc. raised its stake in shares of Eli Lilly and Company by 4.2% in the third quarter. Wealthstream Advisors Inc. now owns 1,332 shares of the company’s stock worth $1,180,000 after buying an additional 54 shares during the period. Zions Bancorporation N.A. lifted its position in shares of Eli Lilly and Company by 12.1% during the 3rd quarter. Zions Bancorporation N.A. now owns 9,330 shares of the company’s stock valued at $8,266,000 after buying an additional 1,004 shares in the last quarter. Bouvel Investment Partners LLC grew its stake in shares of Eli Lilly and Company by 0.6% during the 3rd quarter. Bouvel Investment Partners LLC now owns 6,538 shares of the company’s stock valued at $5,792,000 after acquiring an additional 37 shares during the period. Finally, Plato Investment Management Ltd grew its stake in shares of Eli Lilly and Company by 9.7% during the 3rd quarter. Plato Investment Management Ltd now owns 16,804 shares of the company’s stock valued at $14,872,000 after acquiring an additional 1,481 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $811.30 on Thursday. The company’s 50-day moving average price is $888.32 and its 200-day moving average price is $870.29. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $770.18 billion, a PE ratio of 87.71, a price-to-earnings-growth ratio of 3.10 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The company’s revenue was up 20.4% on a year-over-year basis. On average, equities research analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Barclays lowered their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Citigroup increased their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, BMO Capital Markets increased their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.